146 related articles for article (PubMed ID: 32509289)
1. The case for compulsory licensing during COVID-19.
Wong H
J Glob Health; 2020 Jun; 10(1):010358. PubMed ID: 32509289
[No Abstract] [Full Text] [Related]
2. Compulsory licensing of generic drugs remains mired in quagmires.
Chami G; Wasswa-Kintu S
CMAJ; 2011 Aug; 183(11):E705-6. PubMed ID: 21708968
[No Abstract] [Full Text] [Related]
3. COVID-19: save lives with open intellectual-property licences.
Contreras JL; Eisen M; Peters DM
Nature; 2020 Jul; 583(7818):683. PubMed ID: 32724145
[No Abstract] [Full Text] [Related]
4. Compulsory licensing and access to drugs.
Stavropoulou C; Valletti T
Eur J Health Econ; 2015 Jan; 16(1):83-94. PubMed ID: 24408475
[TBL] [Abstract][Full Text] [Related]
5. Compulsory licensing to regulated licensing: effects on the conflict between innovation and access in the pharmaceutical industry.
Gillat A
Food Drug Law J; 2003; 58(4):711-40. PubMed ID: 15027457
[No Abstract] [Full Text] [Related]
6. Pool patents to get COVID vaccines and drugs to all.
Billette de Villemeur E; Dequiedt V; Versaevel B
Nature; 2021 Mar; 591(7851):529. PubMed ID: 33742180
[No Abstract] [Full Text] [Related]
7. The GO License: only part of the solution.
Batson A; Milstien JB
Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489
[TBL] [Abstract][Full Text] [Related]
8. Taking TRIPS to India--Novartis, patent law, and access to medicines.
Mueller JM
N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
[No Abstract] [Full Text] [Related]
9. Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries.
Guennif S
Appl Health Econ Health Policy; 2017 Oct; 15(5):557-565. PubMed ID: 28120166
[TBL] [Abstract][Full Text] [Related]
10. The need to implement non-industry COVID-19 clinical trials in non-high-income countries.
Dal-Ré R; Carcas AJ; Sreeharan N
J Glob Health; 2020 Jun; 10(1):010351. PubMed ID: 32509284
[No Abstract] [Full Text] [Related]
11. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
12. Compulsory licensing of patents in India.
Chaudhry R
Pharm Pat Anal; 2016 Sep; 5(6):401-406. PubMed ID: 27805847
[TBL] [Abstract][Full Text] [Related]
13. It's time to consider a patent reprieve for COVID vaccines.
Nature; 2021 Apr; 592(7852):7. PubMed ID: 33785920
[No Abstract] [Full Text] [Related]
14. The Legislative Approach and System Improvement of China's Compulsory Licensing for Drug Patents.
Cao Z; Chen Y; Jiang W; Li W
Drug Des Devel Ther; 2021; 15():3717-3731. PubMed ID: 34511881
[TBL] [Abstract][Full Text] [Related]
15. A tragically naive Canadian law for tragically neglected global health.
Attaran A
CMAJ; 2007 Jun; 176(12):1726-7. PubMed ID: 17449707
[No Abstract] [Full Text] [Related]
16. Compulsory licensing in Canada and Thailand: comparing regimes to ensure legitimate use of the WTO rules.
Lybecker KM; Fowler E
J Law Med Ethics; 2009; 37(2):222-39. PubMed ID: 19493068
[TBL] [Abstract][Full Text] [Related]
17. Reforming Canada's Access to Medicines Regime.
Esmail LC
CMAJ; 2007 Jul; 177(3):270. PubMed ID: 17664454
[No Abstract] [Full Text] [Related]
18. Reforming Canada's Access to Medicines Regime.
Elliott R
CMAJ; 2007 Jul; 177(3):270-1. PubMed ID: 17664453
[No Abstract] [Full Text] [Related]
19. TRIPS: whose interests are being served?
Kamal M; Bailey M
Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
[No Abstract] [Full Text] [Related]
20. An exploration of compulsory licensing as an effective policy tool for antiretroviral drugs in India.
Jain D; Darrow JJ
Health Matrix Clevel; 2013; 23(2):425-57. PubMed ID: 24341078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
